Clinical Trials Browser

Phase 2/3 × INDUSTRY × bavituximab × Clear all

NCT02651610 2017-07-11

Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer

Phase 2/3 Withdrawn

Breast Neoplasms